Total: $744.88M | ||||
Company |
Type Of |
Number Of Shares, Units |
Amount |
Investors; Placement Agents; Details (Date)@ |
Aastrom |
Private placement of stock |
4.8S |
$12 |
The private placement concludes an October 2002 deal between Aastrom and Fusion Capital Fund II LLC, which also purchased $12M of stock in the first tranche (1/13) |
Alexion |
Private placement of convertible notes |
N/A |
$150 |
The 1.375% convertible senior notes due 2012 are convertible into stock at $31.46 per share; the total includes the purchase of $25M in notes per the investors' option (1/18) |
Alteon Inc. |
Private placement of stock |
9.5S |
$10 |
The shares were sold from a shelf registration at $1.05 each; Rodman & Renshaw LLC was placement agent (1/7) |
Antigenics |
Private placement of convertible notes |
N/A |
$50 |
The 5.25% convertible senior notes initially are convertible into common stock at $10.76 per share; investors have an option on another $10M in notes (1/20) |
ArQule |
Private placement of stock |
5.78S |
$30.35 |
ArQule sold the shares from a shelf registration at $5.25 each in a direct offering; JP Morgan Securities Inc. was placement (1/25) |
AtheroGenics |
Private placement of convertible notes |
N/A |
$200 |
The 1.5% notes due 2012 are convertible into common shares at an initial price of about $25.92 per share; the total includes $25M in notes purchased under an overallotment option (1/7) |
AVI BioPharma |
Private placement of stock and warrants |
8S and 1.6W |
$24 |
AVI sold the shares from a shelf registration at $3 each; the four-year warrants are exercisable at $5 per share; Rodman & Renshaw LLC was placement agent (1/19) |
Biofusion plc |
Private placement of stock |
5.49S |
£8.2 (US$15.45) |
Biofusion gained a listing on the Alternative Invesment Market concurrent with the placement, giving the company a market cap of about £28.2M; Code Securities Ltd. was adviser and broker for the deal (1/28) |
Biopure Corp. |
Private placement of stock |
22.2S |
$11.3 |
The shares were sold from a shelf registration at $0.51 each to individual and institutional investors; C.E. Unterberg, Towbin LLC was placement agent (1/5) |
CepTor Corp. |
Private placement of units |
0.048U |
$12 |
The company sold 480 units at $25,000 per unit; each unit consists of one share of Series A stock, each convertible into 10,000 common shares, and one three- ear warrant that entitles the holder to purchase 5,000 shares; Brookshire Securities Corp. was placement agent (1/31) |
ChemGenex |
Private placement of stock |
14.9S |
A$8.2 (US$6.3) |
The shares were sold at A$0.55 each; investors included Charter Pacific Corp. Ltd., which maintained its 20.1% stake, Queensland Investment Corp., Merck Sante, HSBC and Acorn Capital (1/24) |
Chromos |
Private placement of stock and warrants |
2.215S and 1.108W |
C$1.06 (US$0.86) |
Units were sold for C$0.48 apiece; each consists of one share and a half a warrant; each whole warrant allows for the purchase of one share at C$0.60 for two years (1/14) |
ConjuChem |
Bought-deal financing |
4.625S |
C$21.74M (US$17.53) |
Orion Securities Inc. and GMP Securities Ltd. co-led the financing, in which shares were sold at $4.70 each; underwriters have an option to purchase up to 694,000 additional shares (1/28) |
CytRx Corp. |
Private placement of stock and warrants |
17.33S and 8.67W |
$21.3 |
The shares were sold for about $1.23 each to institutional investors; warrants are exercisable for $2 per share; Rodman & Renshaw LLC was placement agent (1/21) |
Depomed |
Private placement of stock |
5.036S |
$22.66 |
The shares are being sold from a shelf registration at $4.50 each; Thomas Weisel Partners LLC was placement agent (1/7) |
DOV |
Private placement of convertible notes |
N/A |
$15 |
Purchasers of $65M of convertible subordinated debentures due 2025 exercised their option on another $15M in notes; they have an interest rate of 2.5% and an initial conversion price of $22.75 per share (1/4) |
Genetronics |
Private placement of stock and warrants |
ND |
$3.03 |
Shares were sold at $4.05 each to institutional investors; 80% of the funds are being held until Sept. 30, unless triggered by a milestone earlier; two- year warrants representing 33% of the total are exercisable at $5.50 per share (1/12) |
Geron Corp. |
Warrants exercise |
2S |
$12.5 |
Investors in a November 2004 private placement exercised warrants to purchase 2M shares (1/12) |
GTC |
Private placement of stock |
7.7S |
$10.4 |
The shares were sold from a shelf registration at $1.35 each; SG Cowen & Co. LLC was placement agent (1/24) |
Lorus |
Private placement of convertible notes |
N/A |
$5 |
TEMIC made the second of three planned $5M investments; it has an option to convert the debenture into common stock at $1 per share (1/17) |
Ortec |
Private placement of stock and warrants |
N/A |
$6.4 |
The total includes a $5M private placement and a $1.4M equity transaction; at the same time, Series C preferred shareholders converted the shares into common stock on the same terms; together, about 15.8M shares and five-year warrants to purchase 7.9M warrants were issued (1/6) |
Pharming |
Exercise of warrants and options |
ND |
€7 |
Investors in a February 2004 financing exercised warrants to purchase 3.3M shares at €2 each; also, company insiders exercised 0.5M options and warrants (1/24) |
Pluristem |
Private |
ND |
$0.76 |
Terms of the interim private placement were not disclosed (1/27) |
RegeneRx Bio- |
Private placement of stock and warrants |
1.8S and 0.45W |
$5.86 |
Investors led by Sigma-Tau Group bought the shares at $3.25 each; the three-year warrants are exercisable at $4.06 per share; ThinkEquity Partners LLC was placement agent for the two- tranche deal (1/3) |
Sinovac |
Private placement of units |
0.492S and 0.492W |
$1.48 |
Institutional investors paid $3 per unit, which consisted of one share and a one-year warrant exercisable at $3.35 per share (1/3) |
Sirna |
Warrants exercise |
2.7S |
$6.8 |
Investors exercised warrants for 2.7M shares at about $2.52 each; investors were Sprout Group, Venrock Associates, Oxford Bioscience Partners and Granite Global Ventures; they were issued 1.1M new five-year warrants exercisable at $3.85 per share (1/4) |
Targeted |
Private placement of stock |
3.947S |
$6 |
Celladon Corp. investors Enterprise Partners and Venrock Associates purchased the stock in a directed public offering at $1.52 per share following a collaboration between Celladon and Targeted Genetics (1/4) |
Tripos Inc. |
Private placement of various securities |
N/A |
$4 |
Horizon Technology Finance LLC and Sand Hill Capital invested in the deal that included $3.5M of subordinated debt, 111,606 shares of stock and warrants to purchase 156,250 shares (1/5) |
Vasogen Inc. |
Private placement of stock |
9S |
$42.3 |
Vasogen sold the shares from a shelf registration at $4.70 per share; SG Cowen & Co. LLC was lead agent and sole book manager for the deal; Needham & Co. Inc. was co-lead agent, and A.G. Edwards & Sons Inc. was placement agent (1/28) |
Vion |
Private placement of stock |
10S |
$32.5 |
Vion sold the shares from a shelf registration at $3.25 each to institutional investors; CIBC World Markets Corp. and Leerink Swann & Co. were placement agents (1/26) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
